Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Allergen (AGN) PT Raised to $280 at Leerink Partners Following 4Q
February 9, 2017 8:07 AM ESTLeerink Partners raised its price target on Allergen (NYSE: AGN) to $280.00 (from $271.00) while maintaining a Outperform rating.
Analyst Jason Gerberry commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic... More
Allergan (AGN) Tops Q4 EPS by 14c; Guides Above the Street
February 8, 2017 7:02 AM ESTAllergan (NYSE: AGN) reported Q4 EPS of $3.90, $0.14 better than the analyst estimate of $3.76. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.77 billion.
GUIDANCE:
Allergan sees FY2017 EPS of $15.80-$16.30, versus the consensus of $16.01. Allergan sees FY2017 revenue of $15.5-15.8 billion, versus the consensus of $15.37 billion.
"2016 was a year of transformation for Allergan. We are now a branded biopharmaceutical leader, focused on delivering... More
